Puretech Health Has Initiated A Phase 2A Proof-of-concept Trial Of LYT-300 (Oral Allopregnanolone) In Healthy Volunteers Using A Validated Clinical Model Of Anxiety; Results Are Anticipated By The End Of 2023
Portfolio Pulse from Benzinga Newsdesk
PureTech Health has initiated a Phase 2A proof-of-concept trial of LYT-300 (oral allopregnanolone) in healthy volunteers using a validated clinical model of anxiety. Results are expected by the end of 2023. A Phase 2A trial in patients with postpartum depression is planned to start in 2H 2023.
June 21, 2023 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PureTech Health's initiation of the Phase 2A trial of LYT-300 may positively impact the company's stock in the short term as investors anticipate potential success.
The initiation of the Phase 2A trial of LYT-300 indicates progress in PureTech Health's product pipeline. Positive results from the trial could lead to increased investor interest and potential stock price appreciation. However, the results are expected by the end of 2023, which may limit the short-term impact.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100